Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease with a high prevalence, approximately 1 % in the elderly population. Numerous studies have demonstrated that methamphetamine (MA) intoxication caused the neurological deficits and nigrostriatal damage seen in Parkinsonian conditions, and subsequent rodent studies have found that neurotoxic binge administration of MA reproduced PD-like features, in terms of its symptomatology and pathology. Several anti-Parkinsonian medications have been shown to attenuate the motor impairments and dopaminergic damage induced by MA. In addition, it has been recognized that mitochondrial dysfunction, oxidative stress, pro-apoptosis, proteasomal/autophagic impairment, and neuroinflammation play important roles in inducing MA neurotoxicity. Importantly, MA neurotoxicity has been shown to share a common mechanism of dopaminergic toxicity with that of PD pathogenesis. This review describes the major findings on the neuropathological features and underlying neurotoxic mechanisms induced by MA and compares them with Parkinsonian pathogenesis. Taken together, it is suggested that neurotoxic binge-type administration of MA in rodents is a valid animal model for PD that may provide knowledge on the neuropathogenesis of PD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Açikgöz O, Gönenç S, Kayatekin BM, Uysal N, Pekçetin C, Semin I, Güre A (1998) Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum. Brain Res 813:200–202. https://doi.org/10.1016/s0006-8993(98)01020-8
Adam-Vizi V (2005) Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal 7(9–10):1140–1149. https://doi.org/10.1089/ars.2005.7.1140
Alvarez-Castelao B, Goethals M, Vandekerckhove J, Castaño JG (2014) Mechanism of cleavage of alpha-synuclein by the 20S proteasome and modulation of its degradation by the RedOx state of the N-terminal methionines. Biochim Biophys Acta 1843(2):352–365. https://doi.org/10.1016/j.bbamcr.2013.11.018
Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA, Schapira AH (2010) Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol 67(12):1464–1472. https://doi.org/10.1001/archneurol.2010.198
Ambani LM, Van Woert MH, Murphy S (1975) Brain peroxidase and catalase in Parkinson disease. Arch Neurol 32(2):114–118. https://doi.org/10.1001/archneur.1975.00490440064010
Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, Mouatt-Prigent A, Ruberg M, Hirsch EC, Agid Y (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease. Histol Histopathol 12(1):25–31. https://doi.org/10.14670/HH-12.25
Ares-Santos S, Granado N, Oliva I, O’Shea E, Martin ED, Colado MI, Moratalla R (2012) Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol Dis 45:810–820. https://doi.org/10.1016/j.nbd.2011.11.005
Ares-Santos S, Granado N, Espadas I, Martinez-Murillo R, Moratalla R (2014) Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. Neuropsychopharmacology 39:1066–1080. https://doi.org/10.1038/npp.2013.307
Asanuma M, Miyazaki I, Higashi Y, Cadet JL, Ogawa N (2002) Methamphetamine-induced increase in striatal p53 DNA-binding activity is attenuated in Cu,Zn-superoxide dismutase transgenic mice. Neurosci Lett 325:191–194. https://doi.org/10.1016/s0304-3940(02)00291-4
Asanuma M, Tsuji T, Miyazaki I, Miyoshi K, Ogawa N (2003) Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug. Neurosci Lett 352:13–16. https://doi.org/10.1016/j.neulet.2003.08.015
Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 15(12):1257–1272. https://doi.org/10.1016/S1474-4422(16)30230-7
Bachmann RF, Wang Y, Yuan P, Zhou R, Li X, Alesci S, Du J, Manji HK (2009) Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 12(6):805–822. https://doi.org/10.1017/S1461145708009802
Beauvais G, Atwell K, Jayanthi S, Ladenheim B, Cadet JL (2011) Involvement of dopamine receptors in binge methamphetamine-induced activation of endoplasmic reticulum and mitochondrial stress pathways. PLoS One 6:e28946. https://doi.org/10.1371/journal.pone.0028946
Belcher AM, Feinstein EM, O’Dell SJ, Marshall JF (2008) Methamphetamine influences on recognition memory: comparison of escalating and single-day dosing regimens. Neuropsychopharmacology 33:1453–1463. https://doi.org/10.1038/sj.npp.1301510
Böckelmann R, Wolf G, Ransmayr G, Riederer P (1994) NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson’s disease putamen. J Neural Transm Park Dis Dement Sec. 7(2):115–121. https://doi.org/10.1007/BF02260966
Boger HA, Middaugh LD, Granholm AC, McGinty JF (2009) Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice. Neurobiol Dis 33:459–466. https://doi.org/10.1016/j.nbd.2008.11.013
Brandão PRP, Munhoz RP, Grippe TC, Cardoso FEC, de Almeida E, Castro BM, Titze-de-Almeida R, Tomaz C, Tavares MCH (2020) Cognitive impairment in Parkinson’s disease: A clinical and pathophysiological overview. J Neurol Sci 419:117177. https://doi.org/10.1016/j.jns.2020.117177
Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4 + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119(1):182–192. https://doi.org/10.1172/JCI36470
Brown JM, Quinton MS, Yamamoto BK (2005) Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite. J Neurochem 95(2):429–436. https://doi.org/10.1111/j.1471-4159.2005.03379.x
Brown JM, Gouty S, Iyer V, Rosenberger J, Cox BM (2006) Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression. J Neurochem 98:495–505. https://doi.org/10.1111/j.1471-4159.2006.03902.x
Buhlman L, Damiano M, Bertolin G, Ferrando-Miguel R, Lombès A, Brice A, Corti O (2014) Functional interplay between Parkin and Drp1 in mitochondrial fission and clearance. Biochim Biophys Acta 1843(9):2012–2026. https://doi.org/10.1016/j.bbamcr.2014.05.012
Bukhatwa S, Zeng BY, Rose S, Jenner P (2010) A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Brain Res 1326:174–183. https://doi.org/10.1016/j.brainres.2010.02.045
Burrows KB, Gudelsky G, Yamamoto BK (2000) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur J Pharmacol 398(1):11–18. https://doi.org/10.1016/s0014-2999(00)00264-8
Cadet JL, Sheng P, Ali S, Rothman R, Carlson E, Epstein C (1994) Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem 62:380–383. https://doi.org/10.1046/j.1471-4159.1994.62010380.x
Callaghan RC, Cunningham JK, Sajeev G, Kish SJ (2010) Incidence of Parkinson’s disease among hospital patients with methamphetamine-use disorders. Mov Disord 25:2333–2339. https://doi.org/10.1002/mds.23263
Callaghan RC, Cunningham JK, Sykes J, Kish SJ (2012) Increased risk of Parkinson’s disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 120:35–40. https://doi.org/10.1016/j.drugalcdep.2011.06.013
Cass WA (1997) Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. J Pharmacol Exp Ther 280:105–113
Cass WA, Harned ME, Peters LE, Nath A, Maragos WF (2003) HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res 984:133–142. https://doi.org/10.1016/s0006-8993(03)03122-6
Castaño A, Herrera AJ, Cano J, Machado A (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70(4):1584–1592. https://doi.org/10.1046/j.1471-4159.1998.70041584.x
Castellani RJ, Siedlak SL, Perry G, Smith MA (2000) Sequestration of iron by Lewy bodies in Parkinson’s disease. Acta Neuropathol 100(2):111–114. https://doi.org/10.1007/s004010050001
Castino R, Lazzeri G, Lenzi P, Bellio N, Follo C, Ferrucci M, Fornai F, Isidoro C (2008) Suppression of autophagy precipitates neuronal cell death following low doses of methamphetamine. J Neurochem 106:1426–1439. https://doi.org/10.1111/j.1471-4159.2008.05488.x
Chan P, Di Monte DA, Luo JJ, DeLanney LE, Irwin I, Langston JW (1994) Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J Neurochem 62(6):2484–2487. https://doi.org/10.1046/j.1471-4159.1994.62062484.x
Chan DC (2012) Fusion and fission: interlinked processes critical for mitochondrial health. Annu Rev Genet 46:265–287. https://doi.org/10.1146/annurev-genet-110410-132529
Chao J, Zhang Y, Du L, Zhou R, Wu X, Shen K, Yao H (2017) Molecular mechanisms underlying the involvement of the sigma-1 receptor in methamphetamine-mediated microglial polarization. Sci Rep 7(1):11540. https://doi.org/10.1038/s41598-017-11065-8
Chen H, Chan DC (2009) Mitochondrial dynamics–fusion, fission, movement, and mitophagy–in neurodegenerative diseases. Hum Mol Genet 18(R2):R169–R176. https://doi.org/10.1093/hmg/ddp326
Chen YH, Bae E, Chen H, Yu SJ, Harvey BK, Greig NH, Wang Y (2019) Pifithrin-Alpha Reduces Methamphetamine Neurotoxicity in Cultured Dopaminergic Neurons. Neurotox Res 36(2):347–356. https://doi.org/10.1007/s12640-019-00050-w
Chin MH, Qian WJ, Wang H, Petyuk VA, Bloom JS, Sforza DM, Laćan G, Liu D, Khan AH, Cantor RM, Bigelow DJ, Melega WP, Camp DG, Smith RD, Smith DJ (2008) Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson’s disease. J Proteome Res 7(2):666–677. https://doi.org/10.1021/pr070546l
Choi DY, Liu M, Hunter RL, Cass WA, Pandya JD, Sullivan PG, Shin EJ, Kim HC, Gash DM, Bing G (2009) Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 4(5):e5482. https://doi.org/10.1371/journal.pone.0005482
Chou J, Luo Y, Kuo CC, Powers K, Shen H, Harvey BK, Hoffer BJ, Wang Y (2008) Bone morphogenetic protein-7 reduces toxicity induced by high doses of methamphetamine in rodents. Neuroscience 151(1):92–103. https://doi.org/10.1016/j.neuroscience.2007.10.044
Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH (2009) Alterations in lysosomal and proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 35(3):385–398. https://doi.org/10.1016/j.nbd.2009.05.023
Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, Dawson TM (2004) S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science 304(5675):1328–1331. https://doi.org/10.1126/science.1093891
Coelho-Santos V, Gonçalves J, Fontes-Ribeiro C, Silva AP (2012) Prevention of methamphetamine-induced microglial cell death by TNF-α and IL-6 through activation of the JAK-STAT pathway. J Neuroinflammation 9:103. https://doi.org/10.1186/1742-2094-9-103
Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR (2015) Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment. Drug Alcohol Depend 146:30–38. https://doi.org/10.1016/j.drugalcdep.2014.10.027
da Silva DD, Silva E, Carmo H (2014) Combination effects of amphetamines under hyperthermia - the role played by oxidative stress. J Appl Toxicol 34(6):637–650. https://doi.org/10.1002/jat.2889
Dang DK, Shin EJ, Nam Y, Ryoo S, Jeong JH, Jang CG, Nabeshima T, Hong JS, Kim HC (2016) Apocynin prevents mitochondrial burdens, microglial activation, and pro-apoptosis induced by a toxic dose of methamphetamine in the striatum of mice via inhibition of p47phox activation by ERK. J Neuroinflammation 13:12. https://doi.org/10.1186/s12974-016-0478-x
Dang DK, Shin EJ, Mai AT, Jang CG, Nah SY, Jeong JH, Ledent C, Yamamoto T, Nabeshima T, Onaivi ES, Kim HC (2017a) Genetic or pharmacological depletion of cannabinoid CB1 receptor protects against dopaminergic neurotoxicity induced by methamphetamine in mice. Free Radic Biol Med 108:204–224. https://doi.org/10.1016/j.freeradbiomed.2017.03.033
Dang DK, Shin EJ, Tran HQ, Kim DJ, Jeong JH, Jang CG, Nah SY, Sato H, Nabeshima T, Yoneda Y, Kim HC (2017b) The role of system Xc- in methamphetamine-induced dopaminergic neurotoxicity in mice. Neurochem Int 108:254–265. https://doi.org/10.1016/j.neuint.2017.04.013
Dang DK, Shin EJ, Kim DJ, Tran HQ, Jeong JH, Jang CG, Nah SY, Jeong JH, Byun JK, Ko SK, Bing G, Hong JS, Kim HC (2018a) Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor. J Neuroinflammation 15(1):52. https://doi.org/10.1186/s12974-018-1087-7
Dang DK, Shin EJ, Kim DJ, Tran HQ, Jeong JH, Jang CG, Ottersen OP, Nah SY, Hong JS, Nabeshima T, Kim HC (2018b) PKCδ-dependent p47phox activation mediates methamphetamine-induced dopaminergic neurotoxicity. Free Radic Biol Med 115:318–337. https://doi.org/10.1016/j.freeradbiomed.2017.12.018
de Haan JB, Cristiano F, Iannello RC, Kola I (1995) Cu/Zn-superoxide dismutase and glutathione peroxidase during aging. Biochem Mol Biol Int 35(6):1281–1297
Dehay B, Bové J, Rodríguez-Muela N, Perier C, Recasens A, Boya P, Vila M (2010) Pathogenic lysosomal depletion in Parkinson’s disease. J Neurosci 30(37):12535–12544. https://doi.org/10.1523/JNEUROSCI.1920-10.2010
Deas E, Cremades N, Angelova PR, Ludtmann MH, Yao Z, Chen S, Horrocks MH, Banushi B, Little D, Devine MJ, Gissen P, Klenerman D, Dobson CM, Wood NW, Gandhi S, Abramov AY (2016) Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson’s Disease. Antioxid Redox Signal 24(7):376–391. https://doi.org/10.1089/ars.2015.6343
Deng X, Cadet JL (2000) Methamphetamine-induced apoptosis is attenuated in the striata of copper-zinc superoxide dismutase transgenic mice. Brain Res Mol Brain Res 83:121–124. https://doi.org/10.1016/s0169-328x(00)00169-8
Deng X, Wang Y, Chou J, Cadet JL (2001) Methamphetamine causes widespread apoptosis in the mouse brain: evidence from using an improved TUNEL histochemical method. Brain Res Mol Brain Res 93:64–69. https://doi.org/10.1016/s0169-328x(01)00184-x
Deng X, Cai NS, McCoy MT, Chen W, Trush MA, Cadet JL (2002) Methamphetamine induces apoptosis in an immortalized rat striatal cell line by activating the mitochondrial cell death pathway. Neuropharmacology 42(6):837–845. https://doi.org/10.1016/s0028-3908(02)00034-5
Di Monte DA, Royland JE, Jakowec MW, Langston JW (1996) Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase. J Neurochem 67:2443–2450. https://doi.org/10.1046/j.1471-4159.1996.67062443.x
Doorn KJ, Moors T, Drukarch B, van de Berg WDj, Lucassen PJ, van Dam AM (2014) Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson’s disease patients. Acta Neuropathol Commun 2:90. https://doi.org/10.1186/s40478-014-0090-1
Draoui A, El Hiba O, Aimrane A, El Khiat A, Gamrani H (2020) Parkinson’s disease: From bench to bedside. Rev Neurol (Paris) 176(7–8):543–559. https://doi.org/10.1016/j.neurol.2019.11.002
Duty S, Jenner P (2011) Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164(4):1357–1391. https://doi.org/10.1111/j.1476-5381.2011.01426.x
Eberhardt O, Schulz JB (2003) Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson’s disease. Toxicol Lett 139(2–3):135–151. https://doi.org/10.1016/s0378-4274(02)00428-9
Eisch AJ, Gaffney M, Weihmuller FB, O’Dell SJ, Marshall JF (1992) Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res 598:321–326. https://doi.org/10.1016/0006-8993(92)90201-j
Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K (2010) Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 30(20):6838–6851. https://doi.org/10.1523/JNEUROSCI.5699-09.2010
Endo H, Kamada H, Nito C, Nishi T, Chan PH (2006) Mitochondrial translocation of p53 mediates release of cytochrome c and hippocampal CA1 neuronal death after transient global cerebral ischemia in rats. J Neurosci 26:7974–7983. https://doi.org/10.1523/JNEUROSCI.0897-06.2006
Fantegrossi WE, Ciullo JR, Wakabayashi KT, De La Garza R, Traynor JR, Woods JH (2008) A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 151:533–543. https://doi.org/10.1016/j.neuroscience.2007.11.007
Feng ST, Wang ZZ, Yuan YH, Wang XL, Sun HM, Chen NH, Zhang Y (2020) Dynamin-related protein 1: A protein critical for mitochondrial fission, mitophagy, and neuronal death in Parkinson’s disease. Pharmacol Res 151:104553. https://doi.org/10.1016/j.phrs.2019.104553
Fiesel FC, Ando M, Hudec R, Hill AR, Castanedes-Casey M, Caulfield TR, Moussaud-Lamodière EL, Stankowski JN, Bauer PO, Lorenzo-Betancor O, Ferrer I, Arbelo JM, Siuda J, Chen L, Dawson VL, Dawson TM, Wszolek ZK, Ross OA, Dickson DW, Springer W (2015) Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation. EMBO Rep 16(9):1114–1130. https://doi.org/10.15252/embr.201540514
Flora G, Lee YW, Nath A, Maragos W, Hennig B, Toborek M (2002) Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromolecular Med 2:71–85. https://doi.org/10.1385/NMM:2:1:71
Fornai F, Lenzi P, Gesi M, Soldani P, Ferrucci M, Lazzeri G, Capobianco L, Battaglia G, De Blasi A, Nicoletti F, Paparelli A (2004a) Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J Neurochem 88(1):114–123. https://doi.org/10.1046/j.1471-4159.2003.02137.x
Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Capobianco L, de Blasi A, Battaglia G, Nicoletti F, Ruggieri S, Paparelli A (2004b) Similarities between methamphetamine toxicity and proteasome inhibition. Ann N Y Acad Sci 1025:162–170. https://doi.org/10.1196/annals.1316.021
Fornai F, Lenzi P, Ferrucci M, Lazzeri G, di Poggio AB, Natale G, Busceti CL, Biagioni F, Giusiani M, Ruggieri S, Paparelli A (2005) Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res Bull 65:405–413. https://doi.org/10.1016/j.brainresbull.2005.02.022
Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55(3):259–272. https://doi.org/10.1097/00005072-199603000-00001
Frey K, Kilbourn M, Robinson T (1997) Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 334:273–279. https://doi.org/10.1016/s0014-2999(97)01152-7
Fricks-Gleason AN, German CL, Hoonakker AJ, Friend DM, Ganesh KK, Carver AS, Hanson GR, Fleckenstein AE, Keefe KA (2016) An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicity. Synapse 70(4):139–146. https://doi.org/10.1002/syn.21891
Fujikawa K, Nakahara K, Takasugi N, Nishiya T, Ito A, Uchida K, Uehara T (2020) S-Nitrosylation at the active site decreases the ubiquitin-conjugating activity of ubiquitin-conjugating enzyme E2 D1 (UBE2D1), an ERAD-associated protein. Biochem Biophys Res Commun 524(4):910–915. https://doi.org/10.1016/j.bbrc.2020.02.011
Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter. J Neurosci 18:4861–4869. https://doi.org/10.1523/JNEUROSCI.18-13-04861.1998
Gao HM, Liu B, Zhang W, Hong JS (2003) Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease. FASEB J 17:1954–1956. https://doi.org/10.1096/fj.03-0109fje
Gao J, Liu R, Zhao E, Huang X, Nalls MA, Singleton AB, Chen H (2015) Head injury, potential interaction with genes, and risk for Parkinson’s disease. Parkinsonism Relat Disord 21(3):292–296. https://doi.org/10.1016/j.parkreldis.2014.12.033
Gash DM, Rutland K, Hudson NL, Sullivan PG, Bing G, Cass WA, Pandya JD, Liu M, Choi DY, Hunter RL, Gerhardt GA, Smith CD, Slevin JT, Prince TS (2008) Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol 63(2):184–192. https://doi.org/10.1002/ana.21288
Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290(5493):985–989. https://doi.org/10.1126/science.290.5493.985
Granado N, Ares-Santos S, O’Shea E, Vicario-Abejon C, Colado MI, Moratalla R (2010) Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine. Neurotox Res 18:48–58. https://doi.org/10.1007/s12640-009-9106-1
Granado N, Ares-Santos S, Oliva I, O’Shea E, Martin ED, Colado MI, Moratalla R (2011a) Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis 42:391–403. https://doi.org/10.1016/j.nbd.2011.01.033
Granado N, Lastres-Becker I, Ares-Santos S, Oliva I, Martin E, Cuadrado A, Moratalla R (2011b) Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia 59:1850–1863. https://doi.org/10.1002/glia.21229
Granado N, Ares-Santos S, Moratalla R (2013) Methamphetamine and Parkinson’s disease. Parkinsons Dis 2013:308052. https://doi.org/10.1155/2013/308052
Granado N, Ares-Santos S, Tizabi Y, Moratalla R (2018) Striatal Reinnervation Process after Acute Methamphetamine-Induced Dopaminergic Degeneration in Mice. Neurotox Res 34(3):627–639. https://doi.org/10.1007/s12640-018-9925-z
Graybiel AM, Ohta K, Roffler-Tarlov S (1990) Patterns of cell and fiber vulnerability in the mesostriatal system of the mutant mouse weaver. I. Gradients and compartments. J Neurosci 10(3):720–733. https://doi.org/10.1523/JNEUROSCI.10-03-00720.1990
Guehl D, Bezard E, Dovero S, Boraud T, Bioulac B, Gross C (1999) Trichloroethylene and parkinsonism: a human and experimental observation. Eur J Neurol 6(5):609–611. https://doi.org/10.1046/j.1468-1331.1999.650609.x
Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, Ramos-Escobar N (2019) Neuroinflammation as a Common Feature of Neurodegenerative Disorders. Front Pharmacol 10:1008. https://doi.org/10.3389/fphar.2019.01008
Hall ED, Andrus PK, Oostveen JA, Althaus JS, VonVoigtlander PF (1996) Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 742(1–2):80–88. https://doi.org/10.1016/s0006-8993(96)00968-7
Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59(5):1609–1623. https://doi.org/10.1111/j.1471-4159.1992.tb10990.x
Harish G, Mahadevan A, Srinivas Bharath MM, Shankar SK (2013) Alteration in glutathione content and associated enzyme activities in the synaptic terminals but not in the non-synaptic mitochondria from the frontal cortex of Parkinson’s disease brains. Neurochem Res 38(1):186–200. https://doi.org/10.1007/s11064-012-0907-x
Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000) Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease. Proc Natl Acad Sci U S A 97(6):2875–2880. https://doi.org/10.1073/pnas.040556597
Hartmann A, Troadec JD, Hunot S, Kikly K, Faucheux BA, Mouatt-Prigent A, Ruberg M, Agid Y, Hirsch EC (2001) Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson’s disease, but pathway inhibition results in neuronal necrosis. J Neurosci 21(7):2247–2255. https://doi.org/10.1523/JNEUROSCI.21-07-02247.2001
Harvey BK, Chou J, Shen H, Hoffer BJ, Wang Y (2009) Diadenosine tetraphosphate reduces toxicity caused by high-dose methamphetamine administration. Neurotoxicology 30(3):436–444. https://doi.org/10.1016/j.neuro.2009.02.003
Haslund-Vinding J, McBean G, Jaquet V, Vilhardt F (2017) NADPH oxidases in oxidant production by microglia: activating receptors, pharmacology and association with disease. Br J Pharmacol 174(12):1733–1749. https://doi.org/10.1111/bph.13425
Hastings TG, Lewis DA, Zigmond MJ (1996) Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 93(5):1956–1961. https://doi.org/10.1073/pnas.93.5.1956
Hayashi T, Hirata H, Asanuma M, Ladenheim B, Tsao LI, Cadet JL, Su TP (2001) Delta opioid peptide [D-Ala2, D-Leu5]enkephalin causes a near complete blockade of the neuronal damage caused by a single high dose of methamphetamine: examining the role of p53. Synapse 39:305–312. https://doi.org/10.1002/1098-2396(20010315)39:4<305::AID-SYN1013>3.0.CO;2-E
Hermida-Ameijeiras A, Méndez-Alvarez E, Sánchez-Iglesias S, Sanmartín-Suárez C, Soto-Otero R (2004) Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem Int 45:103–116. https://doi.org/10.1016/j.neuint.2003.11.018
Hirata H, Cadet JL (1997) p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies. J Neurochem 69:780–790. https://doi.org/10.1046/j.1471-4159.1997.69020780.x
Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, Ischiropoulos H (2004) Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 279(46):47746–44753. https://doi.org/10.1074/jbc.M408906200
Hodges AB, Ladenheim B, McCoy MT, Beauvais G, Cai N, Krasnova IN, Cadet JL (2011) Long-term protective effects of methamphetamine preconditioning against single-day methamphetamine toxic challenges. Curr Neuropharmacol 9:35–39. https://doi.org/10.2174/157015911795017344
Hoffmann AC, Minakaki G, Menges S, Salvi R, Savitskiy S, Kazman A, Vicente Miranda H, Mielenz D, Klucken J, Winkler J, Xiang W (2019) Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose. Sci Rep 9(1):544. https://doi.org/10.1038/s41598-018-35811-8
Hogan KA, Staal RG, Sonsalla PK (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J Neurochem 74:2217–2220. https://doi.org/10.1046/j.1471-4159.2000.0742217.x
Hotchkiss AJ, Gibb JW (1980) Long term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 214:257–262
Hou X, Fiesel FC, Truban D, Castanedes Casey M, Lin WL, Soto AI, Tacik P, Rousseau LG, Diehl NN, Heckman MG, Lorenzo-Betancor O, Ferrer I, Arbelo JM, Steele JC, Farrer MJ, Cornejo-Olivas M, Torres L, Mata IF, Graff-Radford NR, Wszolek ZK, Ross OA, Murray ME, Dickson DW, Springer W (2018) Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. Autophagy 14(8):1404–1418. https://doi.org/10.1080/15548627.2018.1461294
Hu Q, Wang G (2016) Mitochondrial dysfunction in Parkinson’s disease. Transl Neurodegener 5:14. https://doi.org/10.1186/s40035-016-0060-6
Huang NK, Wan FJ, Tseng CJ, Tung CS (1997) Nicotinamide attenuates methamphetamine-induced striatal dopamine depletion in rats. Neuroreport 8(8):1883–1885. https://doi.org/10.1097/00001756-199705260-00018
Huang E, Huang H, Guan T, Liu C, Qu D, Xu Y, Yang J, Yan L, Xiong Y, Liang T, Wang Q, Chen L (2019) Involvement of C/EBPβ-related signaling pathway in methamphetamine-induced neuronal autophagy and apoptosis. Toxicol Lett 312:11–21. https://doi.org/10.1016/j.toxlet.2019.05.003
Hunot S, Boissière F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience 72(2):355–363. https://doi.org/10.1016/0306-4522(95)00578-1
Hunter RL, Cheng B, Choi DY, Liu M, Liu S, Cass WA, Bing G (2009) Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res 87(8):1913–1921. https://doi.org/10.1002/jnr.22012
Hyun DH, Lee MH, Halliwell B, Jenner P (2002) Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration? J Neurochem 83(2):360–370. https://doi.org/10.1046/j.1471-4159.2002.01125.x
Imam SZ, Newport GD, Islam F, Slikker W Jr, Ali SF (1999) Selenium, an antioxidant, protects against methamphetamine-induced dopaminergic neurotoxicity. Brain Res 818:575–578. https://doi.org/10.1016/s0006-8993(98)01311-0
Imam SZ, Newport GD, Itzhak Y, Cadet JL, Islam F, Slikker W Jr, Ali SF (2001a) Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J Neurochem 76:745–749. https://doi.org/10.1046/j.1471-4159.2001.00029.x
Imam SZ, Itzhak Y, Cadet JL, Islam F, Slikker W Jr, Ali SF (2001b) Methamphetamine-induced alteration in striatal p53 and bcl-2 expressions in mice. Brain Res Mol Brain Res 91:174–178. https://doi.org/10.1016/s0169-328x(01)00139-5
Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol 106(6):518–526. https://doi.org/10.1007/s00401-003-0766-2
Iravani MM, Syed E, Jackson MJ, Johnston LC, Smith LA, Jenner P (2005) A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur J Neurosci 21(4):841–854. https://doi.org/10.1111/j.1460-9568.2005.03915.x
Itzhak Y, Ali SF (1996) The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J Neurochem 67:1770–1773. https://doi.org/10.1046/j.1471-4159.1996.67041770.x
Itzhak Y, Martin JL, Ali SF (2000) Comparison between the role of the neuronal and inducible nitric oxide synthase in methamphetamine-induced neurotoxicity and sensitization. Ann N Y Acad Sci 914:104–111. https://doi.org/10.1111/j.1749-6632.2000.tb05188.x
Jayanthi S, Deng X, Noailles PA, Ladenheim B, Cadet JL (2004) Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J 18:238–251. https://doi.org/10.1096/fj.03-0295com
Jung BD, Shin EJ, Nguyen XK, Jin CH, Bach JH, Park SJ, Nah SY, Wie MB, Bing G, Kim HC (2010) Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem Int 56:229–244. https://doi.org/10.1016/j.neuint.2009.10.005
Keller JN, Huang FF, Dimayuga ER, Maragos WF (2000) Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic Biol Med 29(10):1037–1042. https://doi.org/10.1016/s0891-5849(00)00412-3
Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG (2009) Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 29:13435–13444. https://doi.org/10.1523/JNEUROSCI.3257-09.2009
Killinger BA, Moszczynska A (2016) Epothilone D prevents binge methamphetamine-mediated loss of striatal dopaminergic markers. J Neurochem 136(3):510–525. https://doi.org/10.1111/jnc.13391
Kim HC, Jhoo WK, Choi DY, Im DH, Shin EJ, Suh JH, Floyd RA, Bing G (1999) Protection of methamphetamine nigrostriatal toxicity by dietary selenium. Brain Res 851:76–86. https://doi.org/10.1016/s0006-8993(99)02122-8
Kim HC, Jhoo WK, Shin EJ, Bing G (2000) Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; comparison with MPTP model. Brain Res 862:247–252. https://doi.org/10.1016/s0006-8993(00)02085-0
Kish SJ, Morito C, Hornykiewicz O (1985) Glutathione peroxidase activity in Parkinson’s disease brain. Neurosci Lett 58(3):343–346. https://doi.org/10.1016/0304-3940(85)90078-3
Klongpanichapak S, Govitrapong P, Sharma SK, Ebadi M (2006) Attenuation of cocaine and methamphetamine neurotoxicity by coenzyme Q10. Neurochem Res 31(3):303–311. https://doi.org/10.1007/s11064-005-9025-3
Knott C, Stern G, Wilkin GP (2000) Inflammatory regulators in Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and – 2. Mol Cell Neurosci 16(6):724–739. https://doi.org/10.1006/mcne.2000.0914
Kocaturk NM, Gozuacik D (2018) Crosstalk between mammalian autophagy and the Ubiquitin-Proteasome system. Front Cell Dev Biol 6:128. https://doi.org/10.3389/fcell.2018.00128
Kochen W, Kohlmüller D, De Biasi P, Ramsay R (2003) The endogeneous formation of highly chlorinated tetrahydro-beta-carbolines as a possible causative mechanism in idiopathic Parkinson’s disease. Adv Exp Med Biol 527:253–263. https://doi.org/10.1007/978-1-4615-0135-0_29
Koizumi H, Morigaki R, Okita S, Nagahiro S, Kaji R, Nakagawa M, Goto S (2013) Response of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease: a potential compensatory role. Front Cell Neurosci 7:74. https://doi.org/10.3389/fncel.2013.00074
Koriem KM, Abdelhamid AZ, Younes HF (2013) Caffeic acid protects tissue antioxidants and DNA content in methamphetamine induced tissue toxicity in Sprague Dawley rats. Toxicol Mech Methods 23:134–143. https://doi.org/10.3109/15376516.2012.730561
Kousik SM, Carvey PM, Napier TC (2014) Methamphetamine self-administration results in persistent dopaminergic pathology: implications for Parkinson’s disease risk and reward-seeking. Eur J Neurosci 40:2707–2714. https://doi.org/10.1111/ejn.12628
Krasnova IN, Justinova Z, Ladenheim B, Jayanthi S, McCoy MT, Barnes C, Warner JE, Goldberg SR, Cadet JL (2010) Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PLoS One 5:e8790. https://doi.org/10.1371/journal.pone.0008790
Krasnova IN, Chiflikyan M, Justinova Z, McCoy MT, Ladenheim B, Jayanthi S, Quintero C, Brannock C, Barnes C, Adair JE, Lehrmann E, Kobeissy FH, Gold MS, Becker KG, Goldberg SR, Cadet JL (2013) CREB phosphorylation regulates striatal transcriptional responses in the self-administration model of methamphetamine addiction in the rat. Neurobiol Dis 58:132–143. https://doi.org/10.1016/j.nbd.2013.05.009
Kroemer G, Galluzzi L, Brenner C (2007) Mitochondrial membrane permeabilization in cell death. Physiol Rev 87:99–163. https://doi.org/10.1152/physrev.00013.2006
Langston JW, Ballard PA Jr (1983) Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 309(5):310. https://doi.org/10.1056/nejm198308043090511
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587):979–980. https://doi.org/10.1126/science.6823561
Lappin JM, Darke S, Farrell M (2018) Methamphetamine use and future risk for Parkinson’s disease: Evidence and clinical implications. Drug Alcohol Depend 187:134–140. https://doi.org/10.1016/j.drugalcdep.2018.02.032
Lau JWS, Senok S, Stadlin A (2000) Methamphetamine-induced oxidative stress in cultured mouse astrocytes. Ann N Y Acad Sci 914:146–156. https://doi.org/10.1111/j.1749-6632.2000.tb05192.x
LaVoie MJ, Hastings TG (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 19:1484–1491. https://doi.org/10.1523/JNEUROSCI.19-04-01484.1999
LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11(11):1214–1221. https://doi.org/10.1038/nm1314
Lazzeri G, Lenzi P, Gesi M, Ferrucci M, Fulceri F, Ruggieri S, Bruno V, Fornai F (2006) In PC12 cells neurotoxicity induced by methamphetamine is related to proteasome inhibition. Ann N Y Acad Sci 1074:174–177. https://doi.org/10.1196/annals.1369.017
Leão AH, Sarmento-Silva AJ, Santos JR, Ribeiro AM, Silva RH (2015) Molecular, neurochemical, and behavioral hallmarks of reserpine as a model for Parkinson’s disease: New perspectives to a long-standing model. Brain Pathol 25(4):377–390. https://doi.org/10.1111/bpa.12253
Lee FJ, Liu F, Pristupa ZB, Niznik HB (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15(6):916–926. https://doi.org/10.1096/fj.00-0334com
Lenzi P, Marongiu R, Falleni A, Gelmetti V, Busceti CL, Michiorri S, Valente EM, Fornai F (2012) A subcellular analysis of genetic modulation of PINK1 on mitochondrial alterations, autophagy and cell death. Arch Ital Biol 150(2–3):194–217. https://doi.org/10.4449/aib.v150i2/3.1417
Li B, Chen R, Chen L, Qiu P, Ai X, Huang E, Huang W, Chen C, Liu C, Lin Z, Xie WB, Wang H (2017) Effects of DDIT4 in Methamphetamine-induced autophagy and apoptosis in dopaminergic neurons. Mol Neurobiol 54(3):1642–1660. https://doi.org/10.1007/s12035-015-9637-9
Li X, Wu F, Xue L, Wang B, Li J, Chen Y, Chen T (2018) Methamphetamine causes neurotoxicity by promoting polarization of macrophages and inflammatory response. Hum Exp Toxicol 37(5):486–495. https://doi.org/10.1177/0960327117714039
Lin M, Chandramani-Shivalingappa P, Jin H, Ghosh A, Anantharam V, Ali S, Kanthasamy AG, Kanthasamy A (2012) Methamphetamine-induced neurotoxicity linked to ubiquitin-proteasome system dysfunction and autophagy-related changes that can be modulated by protein kinase C delta in dopaminergic neuronal cells. Neuroscience 210:308–332. https://doi.org/10.1016/j.neuroscience.2012.03.004
Lindersson E, Beedholm R, Højrup P, Moos T, Gai W, Hendil KB, Jensen PH (2004) Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 279(13):12924–12934. https://doi.org/10.1074/jbc.M306390200
Liu M, Choi DY, Hunter RL, Pandya JD, Cass WA, Sullivan PG, Kim HC, Gash DM, Bing G (2010) Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats. J Neurochem 112(3):773–783. https://doi.org/10.1111/j.1471-4159.2009.06497.x
Liu M, Bing G (2011) Lipopolysaccharide animal models for Parkinson’s disease. Parkinsons Dis. 2011:327089. https://doi.org/10.4061/2011/327089
Liu M, Shin EJ, Dang DK, Jin CH, Lee PH, Jeong JH, Park SJ, Kim YS, Xing B, Xin T, Bing G, Kim HC (2018) Trichloroethylene and Parkinson’s disease: Risk Assessment. Mol Neurobiol 55(7):6201–6214. https://doi.org/10.1007/s12035-017-0830-x
Liu X, Silverstein PS, Singh V, Shah A, Qureshi N, Kumar A (2012) Methamphetamine increases LPS-mediated expression of IL-8, TNF-α and IL-1β in human macrophages through common signaling pathways. PLoS One 7(3):e33822. https://doi.org/10.1371/journal.pone.0033822
Liu B, Traini R, Killinger B, Schneider B, Moszczynska A (2013) Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity. Exp Neurol 247:359–372. https://doi.org/10.1016/j.expneurol.2013.01.001
Lock EA, Zhang J, Checkoway H (2013) Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence. Toxicol Appl Pharmacol 266(3):345–355. https://doi.org/10.1016/j.taap.2012.11.016
Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem 277(41):38884–38894. https://doi.org/10.1074/jbc.M205518200
Lu T, Kim PP, Greig NH, Luo Y (2017) Dopaminergic Neuron-Specific Deletion of p53 Gene Attenuates Methamphetamine Neurotoxicity. Neurotox Res 32(2):218–230. https://doi.org/10.1007/s12640-017-9723-z
Magrinelli F, Picelli A, Tocco P, Federico A, Roncari L, Smania N, Zanette G, Tamburin S (2016) Pathophysiology of motor dysfunction in Parkinson’s disease as the rationale for drug treatment and rehabilitation. Parkinsons Dis 2016:9832839. https://doi.org/10.1155/2016/9832839
Maragos WF, Jakel R, Chesnut D, Pocernich CB, Butterfield DA, St Clair D, Cass WA (2000) Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase. Brain Res 878:218–222. https://doi.org/10.1016/s0006-8993(00)02707-4
Maragos WF, Young KL, Turchan JT, Guseva M, Pauly JR, Nath A, Cass WA (2002) Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem 83:955–963. https://doi.org/10.1046/j.1471-4159.2002.01212.x
Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC (2009) Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 11(11):2685–2700. https://doi.org/10.1089/ARS.2009.2695
McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J, Ye W, Alexander M, Dannals RF, Wong DF, Ricaurte GA (2008) Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62:91–100. https://doi.org/10.1002/syn.20471
McConnell SE, O’Banion MK, Cory-Slechta DA, Olschowka JA, Opanashuk LA (2015) Characterization of binge-dosed methamphetamine-induced neurotoxicity and neuroinflammation. Neurotoxicology 50:131–141. https://doi.org/10.1016/j.neuro.2015.08.006
McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38(8):1285–1291. https://doi.org/10.1212/wnl.38.8.1285
McNaught KS, Jenner P (2001) Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett 297(3):191–194. https://doi.org/10.1016/s0304-3940(00)01701-8
McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol 179(1):38–46. https://doi.org/10.1006/exnr.2002.8050
McNaught KS, Jackson T, JnoBaptiste R, Kapustin A, Olanow CW (2006) Proteasomal dysfunction in sporadic Parkinson’s disease. Neurology 66(10 Suppl 4):S37–S49. https://doi.org/10.1212/wnl.66.10_suppl_4.s37
Mendieta L, Granado N, Aguilera J, Tizabi Y, Moratalla R (2016) Fragment C domain of tetanus toxin mitigates methamphetamine Neurotoxicity and its motor consequences in mice. Int J Neuropsychopharmacol 19(8):pyw021. https://doi.org/10.1093/ijnp/pyw021
Meng Y, Qiao H, Ding J, He Y, Fan H, Li C, Qiu P (2020) Effect of Parkin on methamphetamine-induced α-synuclein degradation dysfunction in vitro and in vivo. Brain Behav 10(4):e01574. https://doi.org/10.1002/brb3.1574
Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180(2):147–150. https://doi.org/10.1016/0304-3940(94)90508-8
Mogi M, Kondo T, Mizuno Y, Nagatsu T (2007) p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett 414(1):94–97. https://doi.org/10.1016/j.neulet.2006.12.003
Monzani E, Nicolis S, Dell’Acqua S, Capucciati A, Bacchella C, Zucca FA, Mosharov EV, Sulzer D, Zecca L, Casella L (2019) Dopamine, oxidative stress and protein-quinone modifications in parkinson’s and other neurodegenerative diseases. Angew Chem Int Ed Engl 58(20):6512–6527. https://doi.org/10.1002/anie.201811122
Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 28:57–87. https://doi.org/10.1146/annurev.neuro.28.061604.135718
Moors TE, Paciotti S, Ingrassia A, Quadri M, Breedveld G, Tasegian A, Chiasserini D, Eusebi P, Duran-Pacheco G, Kremer T, Calabresi P, Bonifati V, Parnetti L, Beccari T, van de Berg WDJ (2019) Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies. Mol Neurobiol 56(2):1344–1355. https://doi.org/10.1007/s12035-018-1090-0
Mor DE, Tsika E, Mazzulli JR, Gould NS, Kim H, Daniels MJ, Doshi S, Gupta P, Grossman JL, Tan VX, Kalb RG, Caldwell KA, Caldwell GA, Wolfe JH, Ischiropoulos H (2017) Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration. Nat Neurosci 20(11):1560–1568. https://doi.org/10.1038/nn.4641
Morgan ME, Gibb JW (1980) Short-term and long-term effects of methamphetamine on biogenic amine metabolism in extra-striatal dopaminergic nuclei. Neuropharmacology 19:989–995. https://doi.org/10.1016/0028-3908(80)90010-6
Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ, Aiken SS, Wickham DJ, Kish SJ (2004) Why is parkinsonism not a feature of human methamphetamine users? Brain 127:363–370. https://doi.org/10.1093/brain/awh046
Moszczynska A, Yamamoto BK (2011) Methamphetamine oxidatively damages parkin and decreases the activity of 26S proteasome in vivo. J Neurochem 116(6):1005–1017. https://doi.org/10.1111/j.1471-4159.2010.07147.x
Murphy KE, Gysbers AM, Abbott SK, Spiro AS, Furuta A, Cooper A, Garner B, Kabuta T, Halliday GM (2015) Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson’s disease. Mov Disord 30(12):1639–1647. https://doi.org/10.1002/mds.26141
Nakahara T, Kuroki T, Ohta E, Kajihata T, Yamada H, Yamanaka M, Hashimoto K, Tsutsumi T, Hirano M, Uchimura H (2003) Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum. Parkinsonism Relat Disord 9(4):213–219. https://doi.org/10.1016/s1353-8020(02)00052-4
Nakamura T, Cieplak P, Cho DH, Godzik A, Lipton SA (2010) S-nitrosylation of Drp1 links excessive mitochondrial fission to neuronal injury in neurodegeneration. Mitochondrion 10(5):573–578. https://doi.org/10.1016/j.mito.2010.04.007
Nakamura T, Lipton SA (2017) ‘SNO’-storms compromise protein activity and mitochondrial metabolism in neurodegenerative disorders. Trends Endocrinol Metab 28(12):879–892. https://doi.org/10.1016/j.tem.2017.10.004
Nam Y, Wie MB, Shin EJ, Nguyen TT, Nah SY, Ko SK, Jeong JH, Jang CG, Kim HC (2015) Ginsenoside Re protects methamphetamine-induced mitochondrial burdens and proapoptosis via genetic inhibition of protein kinase C δ in human neuroblastoma dopaminergic SH-SY5Y cell lines. J Appl Toxicol 35:927–944. https://doi.org/10.1002/jat.3093
Navarro A, Boveris A, Bández MJ, Sánchez-Pino MJ, Gómez C, Muntané G, Ferrer I (2009) Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic Biol Med 46(12):1574–1580. https://doi.org/10.1016/j.freeradbiomed.2009.03.007
Nguyen XK, Lee J, Shin EJ, Dang DK, Jeong JH, Nguyen TT, Nam Y, Cho HJ, Lee JC, Park DH, Jang CG, Hong JS, Nabeshima T, Kim HC (2015) Liposomal melatonin rescues methamphetamine-elicited mitochondrial burdens, pro-apoptosis, and dopaminergic degeneration through the inhibition PKCδ gene. J Pineal Res 58:86–106. https://doi.org/10.1111/jpi.12195
O’Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741–751
Oh CK, Sultan A, Platzer J, Dolatabadi N, Soldner F, McClatchy DB, Diedrich JK, Yates JR 3rd, Ambasudhan R, Nakamura T, Jaenisch R, Lipton SA (2017) S-Nitrosylation of PINK1 attenuates PINK1/Parkin-dependent mitophagy in hiPSC-based Parkinson’s disease models. Cell Rep 21(8):2171–2182. https://doi.org/10.1016/j.celrep.2017.10.068
Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tanaka K, Uchida K (1999) 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem 274(34):23787–23793. https://doi.org/10.1074/jbc.274.34.23787
Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 22:123–144. https://doi.org/10.1146/annurev.neuro.22.1.123
Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72(21 Suppl4):S1–S136. https://doi.org/10.1212/WNL.0b013e3181a1d44c
Pan AL, Hasalliu E, Hasalliu M, Angulo JA (2020) Epigallocatechin gallate mitigates the methamphetamine-induced striatal dopamine terminal toxicity by preventing oxidative stress in the mouse brain. Neurotox Res 37(4):883–892. https://doi.org/10.1007/s12640-020-00177-1
Parameyong A, Charngkaew K, Govitrapong P, Chetsawang B (2013) Melatonin attenuates methamphetamine-induced disturbances in mitochondrial dynamics and degeneration in neuroblastoma SH-SY5Y cells. J Pineal Res 55(3):313–323. https://doi.org/10.1111/jpi.12078
Parameyong A, Govitrapong P, Chetsawang B (2015) Melatonin attenuates the mitochondrial translocation of mitochondrial fission proteins and Bax, cytosolic calcium overload and cell death in methamphetamine-induced toxicity in neuroblastoma SH-SY5Y cells. Mitochondrion 24:1–8. https://doi.org/10.1016/j.mito.2015.07.004
Park MJ, Lee SK, Lim MA, Chung HS, Cho SI, Jang CG, Lee SM (2006) Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity. Brain Res 1109:176–182. https://doi.org/10.1016/j.brainres.2006.06.030
Park M, Hennig B, Toborek M (2012) Methamphetamine alters occludin expression via NADPH oxidase-induced oxidative insult and intact caveolae. J Cell Mol Med 16(2):362–375. https://doi.org/10.1111/j.1582-4934.2011.01320.x
Park JH, Seo YH, Jang JH, Jeong CH, Lee S, Park B (2017) Asiatic acid attenuates methamphetamine-induced neuroinflammation and neurotoxicity through blocking of NF-kB/STAT3/ERK and mitochondria-mediated apoptosis pathway. J Neuroinflammation 14(1):240. https://doi.org/10.1186/s12974-017-1009-0
Park JS, Davis RL, Sue CM (2018) Mitochondrial dysfunction in Parkinson’s disease: New mechanistic insights and therapeutic perspectives. Curr Neurol Neurosci Rep 18(5):21. https://doi.org/10.1007/s11910-018-0829-3
Parker WD Jr, Parks JK, Swerdlow RH (2008) Complex I deficiency in Parkinson’s disease frontal cortex. Brain Res 1189:215–218. https://doi.org/10.1016/j.brainres.2007.10.061
Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, Trojanowski JQ, Lee VM, Ischiropoulos H (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 21(20):8053–8061. https://doi.org/10.1523/JNEUROSCI.21-20-08053.2001
Peng K, Xiao J, Yang L, Ye F, Cao J, Sai Y (2019) Mutual antagonism of PINK1/Parkin and PGC-1α contributes to maintenance of mitochondrial homeostasis in rotenone-induced neurotoxicity. Neurotox Res 35(2):331–343. https://doi.org/10.1007/s12640-018-9957-4
Pham AN, Waite TD (2014) Cu(II)-catalyzed oxidation of dopamine in aqueous solutions: mechanism and kinetics. J Inorg Biochem 137:74–84. https://doi.org/10.1016/j.jinorgbio.2014.03.018
Plotegher N, Duchen MR (2017) Crosstalk between Lysosomes and Mitochondria in Parkinson’s disease. Front Cell Dev Biol 5:110. https://doi.org/10.3389/fcell.2017.00110
Prince JA, Yassin MS, Oreland L (1997) Normalization of cytochrome-c oxidase activity in the rat brain by neuroleptics after chronic treatment with PCP or methamphetamine. Neuropharmacology 36(11–12):1665–1678. https://doi.org/10.1016/s0028-3908(97)00152-4
Qiao D, Xu J, Le C, Huang E, Liu C, Qiu P, Lin Z, Xie WB, Wang H (2014) Insulin- like growth factor binding protein 5 (IGFBP5) mediates methamphetamine-induced dopaminergic neuron apoptosis. Toxicol Lett 230(3):444–453. https://doi.org/10.1016/j.toxlet.2014.08.010
Qiao HH, Zhu LN, Wang Y, Hui JL, Xie WB, Liu C, Chen L, Qiu PM (2019) Implications of alpha-synuclein nitration at tyrosine 39 in methamphetamine-induced neurotoxicity in vitro and in vivo. Neural Regen Res 14(2):319–327. https://doi.org/10.4103/1673-5374.244795
Qin L, Liu Y, Hong JS, Crews FT (2013) NADPH oxidase and aging drive microglial activaton, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia 61:855–868. https://doi.org/10.1002/glia.22479
Racay P, Tatarkova Z, Drgova A, Kaplan P, Dobrota D (2007) Effect of ischemic preconditioning on mitochondrial dysfunction and mitochondrial p53 translocation after transient global cerebral ischemia in rats. Neurochem Res 32:1823–1832. https://doi.org/10.1007/s11064-007-9437-3
Raineri M, Peskin V, Goitia B, Taravini IR, Giorgeri S, Urbano FJ, Bisagno V (2011) Attenuated methamphetamine induced neurotoxicity by modafinil administration in mice. Synapse 65(10):1087–1098. https://doi.org/10.1002/syn.20943
Raineri M, Gonzalez B, Goitia B, Garcia-Rill E, Krasnova IN, Cadet JL, Urbano FJ, Bisagno V (2012) Modafinil abrogates methamphetamine-induced neuroinflammation and apoptotic effects in the mouse striatum. PLoS One 7:e46599. https://doi.org/10.1371/journal.pone.0046599
Raimundo N, Fernández-Mosquera L, Yambire KF, Diogo CV (2016) Mechanisms of communication between mitochondria and lysosomes. Int J Biochem Cell Biol 79:345–349. https://doi.org/10.1016/j.biocel.2016.08.020
Reichel CM, Ramsey LA, Schwendt M, McGinty JF, See RE (2012) Methamphetamine-induced changes in the object recognition memory circuit. Neuropharmacology 62:1119–1126. https://doi.org/10.1016/j.neuropharm.2011.11.003
Reiner DJ, Yu SJ, Shen H, He Y, Bae E, Wang Y (2014) 9-Cis retinoic acid protects against methamphetamine-induced neurotoxicity in nigrostriatal dopamine neurons. Neurotox Res 25(3):248–261. https://doi.org/10.1007/s12640-013-9413-4
Santos D, Esteves AR, Silva DF, Januário C, Cardoso SM (2015) The impact of mitochondrial fusion and fission modulation in sporadic parkinson’ disease. Mol Neurobiol 52(1):573–586. https://doi.org/10.1007/s12035-014-8893-4
Schain M, Kreisl WC (2017) Neuroinflammation in neurodegenerative disorders-a review. Curr Neurol Neurosci Rep 17(3):25. https://doi.org/10.1007/s11910-017-0733-2
Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 333(8649):1269. https://doi.org/10.1016/s0140-6736(89)92366-0
Seemann S, Hainaut P (2005) Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene 24:3853–3863. https://doi.org/10.1038/sj.onc.1208549
Segal DS, Kuczenski R, O’Neil ML, Melega WP, Cho AK (2003) Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28:1730–1740. https://doi.org/10.1038/sj.npp.1300247
Seiden LS, Commins DL, Vosmer G, Axt K, Marek G (1988) Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections. Ann NY Acad Sci 537:161–172. https://doi.org/10.1111/j.1749-6632.1988.tb42104.x
Sekar S, Taghibiglou C (2020) Nuclear accumulation of GAPDH, GluA2 and p53 in post-mortem substantia nigral region of patients with Parkinson’s disease. Neurosci Lett 716:134641. https://doi.org/10.1016/j.neulet.2019.134641
Shah A, Kumar S, Simon SD, Singh DP, Kumar A (2013) HIV gp120- and methamphetamine-mediated oxidative stress induces astrocyte apoptosis via cytochrome P450 2E1. Cell Death Dis 4(10):e850. https://doi.org/10.1038/cddis.2013.374
Shin EJ, Duong CX, Nguyen TX, Bing G, Bach JH, Park DH, Nakayama K, Ali SF, Kanthasamy AG, Cadet JL, Nabeshima T, Kim HC (2011) PKCδ inhibition enhances tyrosine hydroxylase phosphorylation in mice after methamphetamine treatment. Neurochem Int 59:39–50. https://doi.org/10.1016/j.neuint.2011.03.022
Shin EJ, Duong CX, Nguyen XK, Li Z, Bing G, Bach JH, Park DH, Nakayama K, Ali SF, Kanthasamy AG, Cadet JL, Nabeshima T, Kim HC (2012) Role of oxidative stress in methamphetamine-induced dopaminergic toxicity mediated by protein kinase Cδ. Behav Brain Res 232:98–113. https://doi.org/10.1016/j.bbr.2012.04.001
Shin EJ, Shin SW, Nguyen TT, Park DH, Wie MB, Jang CG, Nah SY, Yang BW, Ko SK, Nabeshima T, Kim HC (2014) Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cδ gene. Mol Neurobiol 49:1400–1421. https://doi.org/10.1007/s12035-013-8617-1
Shin EJ, Nam Y, Lee JW, Nguyen PT, Yoo JE, Tran TV, Jeong JH, Jang CG, Oh YJ, Youdim MB, Lee PH, Nabeshima T, Kim HC (2016) N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a selegiline analog, attenuates MPTP-induced dopaminergic toxicity with guaranteed behavioral safety: Involvement of inhibitions of mitochondrial oxidative burdens and p53 gene-elicited pro-apoptotic change. Mol Neurobiol 53(9):6251–6269. https://doi.org/10.1007/s12035-015-9527-1
Shin EJ, Tran HQ, Nguyen PT, Jeong JH, Nah SY, Jang CG, Nabeshima T, Kim HC (2018) Role of mitochondria in methamphetamine-induced dopaminergic neurotoxicity: Involvement in oxidative stress, neuroinflammation, and pro-apoptosis-a review. Neurochem Res 43(1):66–78. https://doi.org/10.1007/s11064-017-2318-5
Shin EJ, Jeong JH, Sharma G, Sharma N, Kim DJ, Pham DT, Trinh QD, Dang DK, Nah SY, Bing G, Kim HC (2019) Protein kinase Cδ mediates methamphetamine-induced dopaminergic neurotoxicity in mice via activation of microsomal epoxide hydrolase. Food Chem Toxicol 133:110761. https://doi.org/10.1016/j.fct.2019.110761
Shin HW, Chung SJ (2012) Drug-induced parkinsonism. J Clin Neurol 8(1):15–21. https://doi.org/10.3988/jcn.2012.8.1.15
Shokrzadeh M, Zamani E, Mehrzad M, Norian Y, Shaki F (2015) Protective effects of propofol against methamphetamine-induced neurotoxicity. Toxicol Int 22(1):92–99. https://doi.org/10.4103/0971-6580.172250
Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD (1994) Glutathione-related enzymes in brain in Parkinson’s disease. Ann Neurol 36(3):356–361. https://doi.org/10.1002/ana.410360306
Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson’s disease. Neurotox Res 11(3–4):151–167. https://doi.org/10.1007/BF03033565
Sipos I, Tretter L, Adam-Vizi V (2003) Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals. J Neurochem 84(1):112–118. https://doi.org/10.1046/j.1471-4159.2003.01513.x
Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson’s disease. Brain Res Mol Brain Res 134(1):57–66. https://doi.org/10.1016/j.molbrainres.2004.09.017
Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B (2003) Aggregated and monomeric alpha-synuclein bind to the S6’ proteasomal protein and inhibit proteasomal function. J Biol Chem 278(14):11753–11759. https://doi.org/10.1074/jbc.M208641200
Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74(3):199–205. https://doi.org/10.1007/BF01244786
Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 142(2):128–130. https://doi.org/10.1016/0304-3940(92)90355-b
Song Z, Ghochani M, McCaffery JM, Frey TG, Chan DC (2009) Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol Biol Cell 20(15):3525–3532. https://doi.org/10.1091/mbc.e09-03-0252
Song L, Cortopassi G (2015) Mitochondrial complex I defects increase ubiquitin in substantia nigra. Brain Res 1594:82–91. https://doi.org/10.1016/j.brainres.2014.11.013
Song C, Charli A, Luo J, Riaz Z, Jin H, Anantharam V, Kanthasamy A, Kanthasamy AG (2019) Mechanistic interplay between autophagy and apoptotic signaling in endosulfan-induced dopaminergic neurotoxicity: Relevance to the adverse outcome pathway in pesticide neurotoxicity. Toxicol Sci 169(2):333–352. https://doi.org/10.1093/toxsci/kfz049
Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED (1996) Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res 738:172–175. https://doi.org/10.1016/0006-8993(96)00995-x
Speidel D (2010) Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol 20:14–24. https://doi.org/10.1016/j.tcb.2009.10.002
Sriram K, Miller DB, O’Callaghan JP (2006) Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem 96:706–718. https://doi.org/10.1111/j.1471-4159.2005.03566.x
Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: A review. Prog Neurobiol 75:406–433. https://doi.org/10.1016/j.pneurobio.2005.04.003
Sun Y, Pham AN, Waite TD (2016) Elucidation of the interplay between Fe(II), Fe(III), and dopamine with relevance to iron solubilization and reactive oxygen species generation by catecholamines. J Neurochem 137(6):955–968. https://doi.org/10.1111/jnc.13615
Tai Y, Chen L, Huang E, Liu C, Yang X, Qiu P, Wang H (2014) Protective effect of alpha-synuclein knockdown on methamphetamine-induced neurotoxicity in dopaminergic neurons. Neural Regen Res 9(9):951–958. https://doi.org/10.4103/1673-5374.133146
Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW (2011) Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect 119(6):866–872. https://doi.org/10.1289/ehp.1002839
Tatton NA (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. Exp Neurol 166(1):29–43. https://doi.org/10.1006/exnr.2000.7489
Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW (1998) A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson’s disease. Ann Neurol 44(3 Suppl 1):S142–S148. https://doi.org/10.1002/ana.410440721
Taylor JM, Main BS, Crack PJ (2013) Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson’s disease. Neurochem Int 62(5):803–819. https://doi.org/10.1016/j.neuint.2012.12.016
Teodorof-Diedrich C, Spector SA (2020) Human Immunodeficiency Virus Type 1 and Methamphetamine-Mediated mitochondrial damage and neuronal degeneration in human neurons. J Virol 94(20):e00924–e00920. https://doi.org/10.1128/JVI.00924-20
Theocharopoulou G (2020) The ubiquitous role of mitochondria in Parkinson and other neurodegenerative diseases. AIMS Neurosci 7(1):43–65. https://doi.org/10.3934/Neuroscience.2020004
Theodore S, Stolberg S, Cass WA, Maragos WF (2006) Human immunodeficiency virus-1 protein tat and methamphetamine interactions. Ann N Y Acad Sci 1074:178–190. https://doi.org/10.1196/annals.1369.018
Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM (2004) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 311:1–7. https://doi.org/10.1124/jpet.104.070961
Thrash B, Karuppagounder SS, Uthayathas S, Suppiramaniam V, Dhanasekaran M (2010) Neurotoxic effects of methamphetamine. Neurochem Res 35:171–179. https://doi.org/10.1007/s11064-009-0042-5
Thrash-Williams B, Karuppagounder SS, Bhattacharya D, Ahuja M, Suppiramaniam V, Dhanasekaran M (2016) Methamphetamine-induced dopaminergic toxicity prevented owing to the neuroprotective effects of salicylic acid. Life Sci 154:24–29. https://doi.org/10.1016/j.lfs.2016.02.072
Tian C, Murrin LC, Zheng JC (2009) Mitochondrial fragmentation is involved in methamphetamine-induced cell death in rat hippocampal neural progenitor cells. PLoS One 4(5):e5546. https://doi.org/10.1371/journal.pone.0005546
Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, Fleckenstein AE (2005) Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. J Pharmacol Exp Ther 314:1087–1092. https://doi.org/10.1124/jpet.105.085951
Tsuji T, Asanuma M, Miyazaki I, Miyoshi K, Ogawa N (2009) Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen. Neurochem Res 34:764–774. https://doi.org/10.1007/s11064-008-9863-x
United Nations Office on Drugs and Crime (2020) World Drug Report 2020. United Nations. https://wdr.unodc.org/wdr2020/field/WDR20_BOOKLET_1.pdf. Accessed 16 Nov 2020
Valian N, Ahmadiani A, Dargahi L (2017) Escalating methamphetamine regimen induces compensatory mechanisms, mitochondrial biogenesis, and GDNF expression, in substantia Nigra. J Cell Biochem 118(6):1369–1378. https://doi.org/10.1002/jcb.25795
Wallace TL, Gudelsky GA, Vorhees CV (1999) Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J Neurosci 19(20):9141–9148. https://doi.org/10.1523/JNEUROSCI.19-20-09141.1999
Walsh SL, Wagner GC (1992) Motor impairments after methamphetamine-induced neurotoxicity in the rat. J Pharmacol Exp Ther 263(2):617–626
Wang Q, Shin EJ, Nguyen XK, Li Q, Bach JH, Bing G, Kim WK, Kim HC, Hong JS (2012) Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice. J Neuroinflammation 9:124. https://doi.org/10.1186/1742-2094-9-124
Wang J, Qian W, Liu J, Zhao J, Yu P, Jiang L, Zhou J, Gao R, Xiao H (2014) Effect of methamphetamine on the microglial damage: role of potassium channel Kv1.3. PLoS One 9(2):e88642. https://doi.org/10.1371/journal.pone.0088642
Wang Q, Qian L, Chen SH, Chu CH, Wilson B, Oyarzabal E, Ali S, Robinson B, Rao D, Hong JS (2015) Post-treatment with ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson’s disease models. Brain 138:1247–1262. https://doi.org/10.1093/brain/awv034
Wang L, Wang Z, Xu X, Zhu R, Bi J, Liu W, Feng X, Wu H, Zhang H, Wu J, Kong W, Yu B, Yu X (2017) Recombinant AAV8-mediated intrastriatal gene delivery of CDNF protects rats against methamphetamine neurotoxicity. Int J Med Sci 14(4):340–347. https://doi.org/10.7150/ijms.18623
Wang B, Chen T, Xue L, Wang J, Jia Y, Li G, Ren H, Wu F, Wu M, Chen Y (2019) Methamphetamine exacerbates neuroinflammatory response to lipopolysaccharide by activating dopamine D1-like receptors. Int Immunopharmacol 73:1–9. https://doi.org/10.1016/j.intimp.2019.04.053
Wen D, An M, Gou H, Liu X, Liu L, Ma C, Cong B (2016) Cholecystokinin-8 inhibits methamphetamine-induced neurotoxicity via an anti-oxidative stress pathway. Neurotoxicology 57:31–38. https://doi.org/10.1016/j.neuro.2016.08.008
Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699–703. https://doi.org/10.1038/nm0696-699
Winklhofer KF, Henn IH, Kay-Jackson PC, Heller U, Tatzelt J (2003) Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J Biol Chem 278(47):47199–47208. https://doi.org/10.1074/jbc.M306769200
Wu CW, Ping YH, Yen JC, Chang CY, Wang SF, Yeh CL, Chi CW, Lee HC (2007) Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SHSY5Y cells during methamphetamine induced apoptosis. Toxicol Appl Pharmacol 220:243–251. https://doi.org/10.1016/j.taap.2007.01.011
Xie XL, Zhou WT, Zhang KK, Chen LJ, Wang Q (2018) METH-induced neurotoxicity is alleviated by Lactulose pretreatment through suppressing oxidative stress and Neuroinflammation in Rat Striatum. Front Neurosci 12:802. https://doi.org/10.3389/fnins.2018.00802
Xu X, Huang E, Luo B, Cai D, Zhao X, Luo Q, Jin Y, Chen L, Wang Q, Liu C, Lin Z, Xie WB, Wang H (2018a) Methamphetamine exposure triggers apoptosis and autophagy in neuronal cells by activating the C/EBPβ-related signaling pathway. FASEB J 32:6737–6759. https://doi.org/10.1096/fj.201701460RRR
Xu E, Liu J, Liu H, Wang X, Xiong H (2018b) Inflammasome activation by methamphetamine potentiates lipopolysaccharide stimulation of IL-1β production in Microglia. J Neuroimmune Pharmacol 13(2):237–253. https://doi.org/10.1007/s11481-018-9780-y
Yan X, Wang B, Hu Y, Wang S, Zhang X (2020) Abnormal mitochondrial quality control in neurodegenerative diseases. Front Cell Neurosci 14:138. https://doi.org/10.3389/fncel.2020.00138
Yin LH, Shen H, Diaz-Ruiz O, Bäckman CM, Bae E, Yu SJ, Wang Y (2012) Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson’s disease. BMC Neurosci 13:120. https://doi.org/10.1186/1471-2202-13-120
Zafar KS, Inayat-Hussain SH, Ross D (2007) A comparative study of proteasomal inhibition and apoptosis induced in N27 mesencephalic cells by dopamine and MG132. J Neurochem 102(3):913–921. https://doi.org/10.1111/j.1471-4159.2007.04637.x
Zhang L, Kitaichi K, Fujimoto Y, Nakayama H, Shimizu E, Iyo M, Hashimoto K (2006) Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 30:1381–1393. https://doi.org/10.1016/j.pnpbp.2006.05.015
Zhang W, Dallas S, Zhang D, Guo JP, Pang H, Wilson B, Miller DS, Chen B, Zhang W, McGeer PL, Hong JS, Zhang J (2007) Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha synuclein. Glia 55:1178–1188. https://doi.org/10.1002/glia.20532
Zhang X, Tobwala S, Ercal N (2012) N-acetylcysteine amide protects against methamphetamine-induced tissue damage in CD-1 mice. Hum Exp Toxicol 31:931–944. https://doi.org/10.1177/0960327112438287
Zhang Z, Liu L, Jiang X, Zhai S, Xing D (2016) The essential role of Drp1 and its regulation by S-Nitrosylation of parkin in dopaminergic neurodegeneration: Implications for Parkinson’s disease. Antioxid Redox Signal 25(11):609–622. https://doi.org/10.1089/ars.2016.6634
Zhang W, Gao JH, Yan ZF, Huang XY, Guo P, Sun L, Liu Z, Hu Y, Zuo LJ, Yu SY, Cao CJ, Wang XM, Hong JS (2018) Minimally Toxic Dose of Lipopolysaccharide and α-Synuclein Oligomer Elicit Synergistic Dopaminergic Neurodegeneration: Role and Mechanism of Microglial NOX2 Activation. Mol Neurobiol 55(1):619–632. https://doi.org/10.1007/s12035-016-0308-2
Zhu JP, Xu W, Angulo JA (2006) Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice. Neuroscience 140:607–622.https://doi.org/10.1016/j.neuroscience.2006.02.055
Acknowledgements
This study was supported by a Grant (#19182MFDS410) from the Korea Food and Drug Administration and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (#NRF-2019R1A2C4070161 and #NRF-2019R1I1A3A01063609), Republic of Korea. The English in this document has been checked by a professional English editor (Editage by CACTUS Communications Inc., Seoul, Republic of korea, www.editage.co.kr, https://app.editage.co.kr/orders/download-files/WQQNG_3 and https://app.editage.co.kr/orders/download-files/WQQNG_9).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shin, EJ., Jeong, J.H., Hwang, Y. et al. Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson’s disease. Arch. Pharm. Res. 44, 668–688 (2021). https://doi.org/10.1007/s12272-021-01341-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-021-01341-7